Table 4.

Univariate and multivariate analysis of prognostic factors for survival

TTP
OS
Univariate
Multivariate
Univariate
Multivariate
Median (mo)PP [HR (95% CI)]Median (mo)PP [HR (95% CI)]
Age (y)
    <602.60.65618.30.293
    ≥602.711.2
Sex
    Female8.6<0.0010.002 [0.39 (0.22-0.70)]NR<0.001<0.001 [0.17 (0.08-0.40)]
    Male1.85.3
ECOG performance status
    0-12.60.35215.00.0050.005 [0.29 (0.12-0.69)]
    2-32.74.7
Stage
    IIIB3.80.30111.70.604
    IV2.513.7
Histology
    Adenocarcinoma3.90.001NR0.001
    Others2.07.2
Smoking status
    Never smoker5.60.002NR<0.001
    Smoker1.95.3
Erlotinib
    First line4.00.35219.20.465
    ≥Second line2.512.0
Skin rash after treatment
    Yes2.70.00319.2<0.0010.036 [0.45 (0.21-0.95)]
    No1.74.3
EGFR mutation (exon 18, 19, or 21; n = 92)
    Yes8.60.0030.020 [0.47 (0.25-0.89)]NR0.023
    No2.510.8
EFGR amplification (n = 88)
    Yes5.80.001NR0.033
    No1.810.1
EGFR expression (n = 75)
    Yes2.50.148NR0.365
    No2.712.9